Laboratory of Advanced Pharmaceutical Process Engineering, Gifu Pharmaceutical University, Gifu 502-8585, Japan; RICOH Co., Ltd., Kanagawa 243-0460, Japan.
RICOH Co., Ltd., Kanagawa 243-0460, Japan.
Int J Pharm. 2023 Mar 25;635:122731. doi: 10.1016/j.ijpharm.2023.122731. Epub 2023 Feb 21.
We developed a method for the preparation of PLGA particles exhibiting long-term sustained-release of entrapped drugs. The fine droplet drying (FDD) technology using a new injection system based on ink-jet injection technology was adapted as the preparation method. PLGA microspheres containing TRITC-dextran, acetaminophen, and albumin as model drugs were prepared by the FDD technology. The resultant microspheres were uniform in size, with average particle sizes ranging from 16.3 to 33.0 μm and SPAN factors ranging from 0.49 to 0.77. The encapsulation efficiency of drugs showed high values ranging from 75 to 99 wt% of the total amount of water-soluble drug contained in the particles. In an investigation of the optimal operation conditions of the FDD technology, the dew point temperature of the dryer air stream was found to be an important factor for controlling the initial burst of the prepared particles. The TRITC-dextran-containing PLGA microspheres were confirmed to exhibit long-term sustained release for about 90 days, and the mechanism was found to be PLGA degradation rate-limiting. Based on these results, we concluded that long-term sustained-released PLGA particles can be prepared by using FDD technology under a suitable drying condition for controlling the initial burst.
我们开发了一种制备具有长期持续释放包埋药物的 PLGA 颗粒的方法。采用基于喷墨注射技术的新型注射系统的精细液滴干燥(FDD)技术被用作制备方法。通过 FDD 技术制备了载有 TRITC-葡聚糖、对乙酰氨基酚和白蛋白作为模型药物的 PLGA 微球。所得微球粒径均匀,平均粒径为 16.3 至 33.0μm,SPAN 因子为 0.49 至 0.77。药物的包封效率表现出高值,范围为 75 至 99wt%的包含在颗粒中的水溶性药物的总量。在对 FDD 技术的最佳操作条件的研究中,发现干燥气流的露点温度是控制所制备颗粒的初始突释的重要因素。含有 TRITC-葡聚糖的 PLGA 微球被证实可以持续释放约 90 天,其机制被发现是 PLGA 降解速率限制。基于这些结果,我们得出结论,通过使用 FDD 技术在控制初始突释的合适干燥条件下,可以制备具有长期持续释放的 PLGA 颗粒。